{"filing":{"accession_number":"0001193125-26-341270","cik":"0001232524","ticker":"JAZZ","company_name":"Jazz Pharmaceuticals plc","form":"8-K","filing_date":"2026-08-10","report_date":"2026-08-10","primary_document":"d106596d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1232524/000119312526341270/d106596d8k.htm"},"events":[{"id":26373,"run_id":23964,"accession_number":"0001193125-26-341270","anchor_item_number":"7.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"summary":"Jazz Pharmaceuticals announced entry into a definitive agreement to acquire Actio Biosciences for $820 million upfront plus up to $500 million in contingent consideration. The press release explicitly states the companies \"have entered into a definitive agreement\" and describes this as a material strategic expansion of Jazz's rare epilepsy portfolio. This is a classic material acquisition disclosure under Item 1.01 of Form 8-K, disclosed via Item 7.01 Regulation FD Disclosure.","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-08-10","form":"8-K","submitted_at":null,"items":[{"id":27469,"accession_number":"0001193125-26-341270","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Jazz Pharmaceuticals announced entry into a definitive agreement to acquire Actio Biosciences for $820 million upfront plus up to $500 million in contingent consideration. The press release explicitly states the companies \"have entered into a definitive agreement\" and describes this as a material strategic expansion of Jazz's rare epilepsy portfolio. This is a classic material acquisition disclosure under Item 1.01 of Form 8-K, disclosed via Item 7.01 Regulation FD Disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:41:40.910933+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":27469,"accession_number":"0001193125-26-341270","item_number":"7.01","item_title":null,"event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.98,"reasoning":"Jazz Pharmaceuticals announced entry into a definitive agreement to acquire Actio Biosciences for $820 million upfront plus up to $500 million in contingent consideration. The press release explicitly states the companies \"have entered into a definitive agreement\" and describes this as a material strategic expansion of Jazz's rare epilepsy portfolio. This is a classic material acquisition disclosure under Item 1.01 of Form 8-K, disclosed via Item 7.01 Regulation FD Disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-10T11:41:40.910933+00:00","company_name":"Jazz Pharmaceuticals plc","ticker":"JAZZ","filing_date":"2026-08-10"}]}